NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression
BeiGene a global biotechnology company, today announced that the China National Medical Products Administration (NMPA) granted approval for the company
